AC-1001 H3 CDR peptide induces apoptosis and signs of autophagy in vitro and exhibits antimetastatic activity in a syngeneic melanoma model by Rabaca, Aline N et al.
AC-1001 H3 CDR peptide induces apoptosis and signs of
autophagy in vitro and exhibits antimetastatic activity in a
syngeneic melanoma model
Aline N. Rabaca1, Denise C. Arruda1,2, Carlos R. Figueiredo1, Mariana H. Massaoka1,
Camyla F. Farias1, Dayane B. Tada3, Vera C. Maia4, Pedro I. Silva Junior5, Natalia Girola1,
Fernando Real6, Renato A. Mortara6, Luciano Polonelli7 and Luiz R. Travassos1
1 Unidade de Oncologia Experimental (UNONEX), Universidade Federal de S~ao Paulo (UNIFESP), Brazil
2 Nucleo Integrado de Biotecnologia, Universidade de Mogi das Cruzes, Brazil
3 Departamento de Cie^ncia e Tecnologia, Universidade Federal de S~ao Paulo (UNIFESP), S~ao Jose dos Campos, Brazil
4 Recepta Biopharma, S~ao Paulo, Brazil
5 Laboratorio Especial de Toxinologia Aplicada, Instituto Butantan, S~ao Paulo, Brazil
6 Departamento de Parasitologia, Universidade Federal de S~ao Paulo (UNIFESP), Brazil
7 Microbiology and Virology Unit, Department of Biomedical, Biotechnological and Translational Sciences, Universita degli Studi di Parma,
Italy
Keywords
apoptosis; autophagy; immunoglobulin CDR;
melanoma; peptides
Correspondence
L. R. Travassos, Departamento de
Microbiologia, Imunologia e Parasitologia,
Unidade de Oncologia Experimental
(UNONEX), Universidade Federal de S~ao
Paulo, Rua Botucatu 862, 8 andar, S~ao
Paulo, SP 04023-062, Brazil
Fax: +55 11 55715877
Tel: +55 11 55764551
E-mail: luiztravassos@gmail.com
ANR and DCA share the first authorship.
(Received 11 August 2015, revised 20 April
2016, accepted 21 April 2016)
doi:10.1002/2211-5463.12080
Antibody-derived peptides modulate functions of the immune system and
are a source of anti-infective and antitumor substances. Recent studies
have shown that they comprise amino acid sequences of immunoglobulin
complementarity-determining regions, but also fragments of constant
regions. VH CDR3 of murine mAb AC-1001 displays antimetastatic activi-
ties using B16F10-Nex2 murine melanoma cells in a syngeneic model. The
peptide was cytotoxic in vitro in murine and human melanoma cells induc-
ing reactive oxygen species (ROS) and apoptosis by the intrinsic pathway.
Signs of autophagy were also suggested by the increased expression of
LC3/LC3II and Beclin 1 and by ultrastructural evidence. AC-1001 H3
bound to both G- and F-actin and inhibited tumor cell migration. These
results are important evidence of the antitumor activity of Ig CDR-derived
peptides.
Melanoma is the most aggressive skin cancer [1]
responsible for 80% of lethal cases [2,3]. The malig-
nant tumor arises from transformed melanocytes,
which originate from the neural-crest and accumulate
genomic mutations leading to uncontrolled
proliferation, invasion, and metastasis [4,5]. Melanoma
stem cells can also be isolated representing a popula-
tion highly enriched in the neural-crest growth factor
receptor (CD271) [6]. Conventional anticancer therapy
has not been effective in advanced melanoma [4,7].
Abbreviations
CDR, complementary determining regions; DHE, dihydroethidium; Ig-VH, heavy chain variable region on immunoglobulin; MTT, 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide; pNA, para-nitroaniline; ROS, reactive oxygen species; TEM, transmission electron
microscopy; TMRE, tetramethylrhodamine ethyl ester; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end-labeling.
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Immune checkpoint monoclonal antibodies are encour-
aging therapeutic agents being tested against the meta-
static tumor [8].
Anticancer peptides from natural sources are emerg-
ing as potential therapeutic agents, mainly because of
their small size, low immunogenicity, better tissue pen-
etration, and easy production, with the possibility of
low-cost structural modifications. They can display a
wide range of effects, such as necrotic, apoptotic, func-
tion blocking, anti-angiogenic, and immunostimulatory
activities [9].
In a collaborative study, Polonelli et al. [10] showed
that immunoglubulins may represent an unlimited
source of bioactive peptides, particularly those corre-
sponding to the complementarity-determining regions
(CDRs). Some of these CDR-derived peptides have
been shown to display differential antimicrobial, antivi-
ral, immunomodulatory, and antitumor activities,
independently of the specificity of the native antibody
[10,11]. In particular, the peptides based on the CDR 3
of the heavy chain (H3), could act as micro-antibodies
and reproduce some properties of the original
immunoglobulin [12,13].
Polonelli et al. [10] showed that the synthetic pep-
tide corresponding to the human mAb HuA CDR L1,
but not the mAb itself specific for difucosyl human
blood group A, caused apoptosis in vitro on melanoma
cells and exerted antimetastatic effects in vivo [10].
Human (HuA) and mouse (AC-1001) monoclonal anti-
bodies to blood group A recognize the same epitope
although they have completely different sequences [14].
A recent study established that the noncandidacidal
synthetic peptide with the sequence of the CDR H3 of
mAb AC-1001 exhibited antifungal effect against
systemic candidiasis based on an immunomodulatory
effect [15].
Based on the cross-cytotoxicity of CDR peptides
using different cell targets, we aimed, in this study, at
investigating the antitumor activity of AC-1001 H3
in vitro and in vivo. The peptide induced apoptosis and
signs of autophagy in vitro, using B16F10-Nex2 mela-
noma cells, targeting b-actin. Furthermore, the peptide
inhibited tumor cell metastasis in vivo, in a syngeneic
mouse model, standing as a potential anticancer drug.
Materials and methods
Cell lines
The human cell lines A2058 (melanoma) and the murine
cell line B16F10 (melanoma) were provided by the Ludwig
Institute for Cancer Research, S~ao Paulo, Brazil. The sub-
line B16F10-Nex2 was established at the Experimental
Oncology Unit, Federal University of S~ao Paulo, as
described previously [16] and is deposited at Banco de
Celulas do Rio de Janeiro, BCRJ No. 0342. The human
umbilical vein endothelial cell (HUVEC) was provided by
Prof. Helena Nader, Federal University of S~ao Paulo and
the human fibroblast cell (T75) was provided by Prof.
Oswaldo Keith Okamoto, University of S~ao Paulo. Cell
lines were maintained in RPMI 1640 (Gibco, Grand Island,
NY, USA) or DMEM (Gibco) supplemented with 10 mM
HEPES (Sigma-Aldrich, St Louis, MO, USA), 24 mM
sodium bicarbonate, 40 mgL1 gentamicin (Hipolabor,
Sabara, MG, Brazil), pH 7.2, and 10% fetal bovine serum
(Gibco) at 37 °C in a humidified atmosphere containing
5% CO2.
Peptides
Peptide AC-1001 H3 (GQYGNLWFAY-NH2) and the
scrambled peptide (YAFGWNQLYG-NH2) were synthe-
sized by Peptide 2.0 (Chantilly, VA, USA) and diluted in
2% DMSO, 20% Milli-Q-distilled water, and RPMI 1640
medium in this order for stable solubility.
Cell viability assay
Cells were cultivated (104/well) in 96-well plates and incu-
bated with AC-1001 H3 or with scrambled peptide at dif-
ferent concentrations: 0, 0.08, 0.175, and 0.35 mM at 37 °C
in a humidified atmosphere containing 5% CO2. After 18 h
incubation, MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-
tetrazolium bromide) (Sigma-Aldrich) solution
(5 mgmL1) was added to each well and incubated at
37 °C. After 3 h, 10% SDS was directly added to dissolve
the formazan crystals and, on the following day, absor-
bance was measured using an automated spectrophotomet-
ric plate reader (SpectraMax-M2, Software Pro 5.4;
Molecular Devices, Sunnyvale, CA, USA) at 570 nm. Cell
viability is expressed as percent values in comparison with
untreated cells.
Superoxide anions
Superoxide anions production was determined by dihy-
droethidium (DHE) assay according to the manufacturer’s
instructions (Invitrogen, Carlsbad, CA, USA). Briefly,
B16F10-Nex2 cells (104/well) were cultivated in 48-well
plates, treated with 0.35 mM AC-1001 H3 or medium (con-
trol) during 18 h at 37 °C and then incubated with 5 lM
DHE for 30 min at room temperature. Cells were treated
with 5 mM H2O2 at 37 °C for 20 min as a positive control.
The cells were immediately analyzed by fluorescence micro-
scopy in an Olympus BX-51 microscope using a 409 objec-
tive. DHE oxidation was observed by the red fluorescence.
Images were processed with IMAGEJ.
886 FEBS Open Bio 6 (2016) 885–901 ª 2016 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
Apoptotic CDR H3 peptide inhibits melanoma metastasis A. N. Rabaca et al.
Chromatin condensation
The chromatin condensation analysis was determined using
Hoechst 33342 (Invitrogen), which intercalates within DNA
emitting blue fluorescence. B16F10-Nex2 cells (104/well)
were cultivated in 48-well plates and treated with 0.35 mM
AC-1001 H3 or medium (control) during 18 h at 37 °C.
They were then fixed with 2% formaldehyde for 30 min
and stained with 2 lM Hoechst 33342 for 10 min at room
temperature. The cells were analyzed by fluorescence micro-
scopy in an Olympus BX-51 microscope using a 209 objec-
tive. Apoptotic cells were detected by chromatin
condensation. Images were processed with IMAGEJ.
TUNEL assay
The TUNEL (terminal deoxynucleotidyl transferase dUTP
nick end-labeling) assay, detects DNA fragmentation by
labeling the terminal end of nucleic acids. It was used
according to the manufacturer’s protocol (‘In Situ Cell
Death Detection kit, AP’; Roche Molecular Biochemicals,
Mannheim, Germany). Briefly, B16F10-Nex2 cells (104/
well) were cultivated in 48-well plates and treated with
0.35 mM AC-1001 H3 or medium (control) for 18 h at
37 °C. Treatment with 2 lgmL1 Actinomycin D (Sigma-
Aldrich) for 2 h was used as a positive control. Cells were
fixed with 2% formaldehyde for 30 min and were perme-
abilized with 0.1% Triton X-100 for 30 min at room tem-
perature. After washing, the cells were incubated with
50 lL of TUNEL reaction mixture for 1 h, at 37 °C and
protected from light. These cells were also stained with
10 lgmL1 DAPI (Invitrogen) for 10 min. The cells were
analyzed by fluorescence microscopy in an Olympus BX-51
microscope using a 209 objective. Images were processed
with IMAGEJ.
Caspase activation
Activation of caspases 3, 8, and 9 was determined by the
Apotarget Caspase Colorimetric Protease Assay Sampler
Kit (Invitrogen) according to the manufacturer’s instruc-
tions. In summary, B16F10-Nex2 cells (3 9 105/well) were
cultivated in 6-well plates and treated with 0.35 mM AC-
1001 H3 or medium (control) during 12 h at 37 °C. After
washing, they were harvested, pelleted, and resuspended in
50 lL of chilled cell lysis buffer and incubated in ice for
10 min. The lysate was centrifuged at 10 000 g for 1 min
and the supernatant was transferred to a fresh tube. Brad-
ford method was used to determine the protein concentra-
tion and the extract was diluted to 3 mgmL1. An equal
volume (50 lL) of 29 Reaction Buffer with 10 mM DTT
was added to each sample. The samples were incubated
with 200 lM of the substrates, DEVD-pNA (caspase-3),
IETD-pNA (caspase-8), and LEHD-pNA (caspase-9), at
37 °C for 2 h in a 96-well plate. The absorption of light by
free para-nitroaniline (pNA) as a result of the synthetic
substrates-pNA cleavage by caspases was quantified using a
microplate reader (SpectraMax-M2, Software Pro 5.4;
Molecular Devices) at 405 nm.
Morphological alterations – transmission electron
microscopy
B16F10-Nex2 cells (104/well) were cultivated in 24-well
plates and treated with 0.35 mM AC-1001 H3 overnight at
37 °C. They were fixed in a solution of 2.5% glutaralde-
hyde and 2% formaldehyde in 0.1 M sodium cacodylate
buffer, pH 7.2, at room temperature for 3 h. After washing
in the same buffer for 10 min, they were fixed with 1%
osmium tetroxide in 0.1 M cacodylate at pH7.2 for 30 min,
and washed with water for 10 min at room temperature.
Subsequently, cells were treated with aqueous 0.4% uranyl
acetate for 30 min and washed again for 10 min. Cells were
then dehydrated in graded ethanol (70%, 90%, and 100%),
treated quickly with propylene oxide, and embedded in
SPURR. Ultrathin sections were collected on grids and
stained in alcoholic 1% uranyl acetate and in lead citrate
prior to examination in a Jeol 100 CX electron microscope
(Tokyo, Japan) to investigate the morphological alterations
induced by AC-1001 H3 treatment.
Phosphatidylserine translocation
The ‘Annexin V-FITC Apoptosis Detection Kit’ (Sigma-
Aldrich), that measures the binding of annexin V-FITC to
translocated phosphatidylserine in the membrane of apop-
totic cells and the binding of propidium iodide to DNA
when the cell membrane has been compromised (necrotic
cells), was used to identify apoptotic and necrotic cells by
flow cytometry. B16F10-Nex2 cells (2 9 105/well) were cul-
tivated in 6-well plates and treated with 0.35 mM AC-1001
H3 or RPMI with 2% DMSO during 12 h at 37 °C. After
washing, they were harvested with a cell scraper, pelleted
and washed again twice. The samples were then resus-
pended in binding buffer (10 mM HEPES/NaOH, pH 7.5,
140 mM NaCl, and 2.5 mM CaCl2) in the presence of pro-
pidium iodide (0.5 lgmL1) and annexin V (2 lgmL1)
for 10 min at room temperature in the dark and
immediately analyzed by flow cytometry (FACSCanto II;
BD Bioscience, Franklin Lakes, NJ, USA; using FACSDIVA
software; BD Bioscience and FLOWJO software; TreeStar
Inc., Ashland, OR, USA).
Mitochondrial membrane-potential disruption
B16F10-Nex2 cells (2 9 105/well) were cultivated in 6-well
plates and treated with 0.35 mM AC-1001 H3, medium
(control) or the scrambled peptide overnight at 37 °C. Cells
were gently washed, harvested with PBS-EDTA, pelleted,
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and stained with 20 nM tetramethylrhodamine ethyl ester
(TMRE; Molecular Probes, Eugene, OR, USA) for 10 min
at 37 °C and protected from light. TMRE is a cationic
lipophilic dye that accumulates in active mitochondria (neg-
atively charged) and is unable to be sequestered in depolar-
ized or inactive mitochondria. Fluorescence was measured
by FACSCanto II (BD Bioscience), using FACSDIVA soft-
ware (BD Bioscience) and analyzed using FLOWJO software
(TreeStar Inc.).
LC3 and Beclin 1 labeling
Autophagy phenotypic traits were analyzed through confo-
cal microscopy, using antibodies against LC3 and Beclin
proteins, essential for the formation of autophagosomes.
B16F10-Nex2 cells (104) were cultivated in round glass cov-
erslips and treated with 0.35 mM AC-1001 H3 or medium
with 2% DMSO (control) overnight at 37 °C. They were
fixed with 2% formaldehyde for 30 min and permeabilized
with Triton X-100 0.1% for 30 min at room temperature.
After blocking with immunofluorescence buffer (150 mM
NaCl, 50 mM Tris, 0.1% Tween, and 0.25% BSA) for 1 h,
at 37 °C, they were incubated with 1 : 500 anti-LC3 or
anti-Beclin (both from Sigma-Aldrich) for 3 h, following
incubation with 1 : 1000 anti-rabbit-AlexaFluor 488 (Invit-
rogen, Eugene, OR, USA) for 1.5 h. These cells were also
stained with 10 lgmL1 DAPI (Invitrogen) for 10 min.
The coverslips were mounted on slides with 4 lL of Vec-
tashield (Sigma) and observed in a Confocal Leica SP5
microscope, with a 63 9 1.4 oil objective; the Z series was
obtained according with sampling criteria built in the soft-
ware. Images were processed using IMAGEJ.
Western blotting
B16F10-Nex2 cells were treated with AC-1001 H3
(0.35 mM) or medium (control) overnight, washed with
PBS and lysed for 15 min at 4 °C with ice cold RIPA buf-
fer (50 mM Tris-Cl, pH 7.5, 150 mM NaCl, 1% Nonidet P-
40, 0.5% sodium deoxycholate, and 0.1% SDS) supple-
mented with protease and phosphatase inhibitors (Sigma-
Aldrich). After sonication, samples were centrifuged and
the supernatants were collected. The protein concentration
of lysates was measured using Bradford method. Proteins
from each cell lysate were separated by SDS gel elec-
trophoresis and transferred to a nitrocellulose membrane
(Millipore, Billerica, MA, USA), which was blocked in
TPBS (PBS with 0.05% Tween-20) with 5% skim milk.
After washing, the membranes were incubated overnight at
4 °C with 1 : 1000 of primary antibody anti-LC3 (Sigma-
Aldrich) and anti-GAPDH (Millipore, Temecula, CA,
USA) was used as loading control. Then, they were washed
again and incubated for 1 h at room temperature with the
secondary antibody anti-rabbit IgG-HRP and anti-mouse
IgG-HRP, respectively (both from Cell Signaling
Technology, Beverly, MA, USA). Protein band were
detected using the UVItec Alliance Gel Documentation
System (UVItec, Cambridge, UK). Band area intensity was
quantified using IMAGEJ.
For an expression kinetics of Beclin 1 and caspase 3,
B16F10-Nex2, and A2058 cells (5 9 104) were treated with
0.35 mM of AC1001 peptide for 4, 8 and 16 h. After treat-
ment, proteins in cell lysates were analyzed by western
blotting as described elsewhere [17]. The following anti-
bodies were used: anti-a-tubulin (Sigma Aldrich), anti-
Beclin 1, anti-caspase-3 or cleaved caspase-3 purchased
from Cell Signaling Technology. a-tubulin was used as
loading control. Secondary antibodies conjugated with IgG
horseradish peroxidase were purchased from Cell Signaling
Technology.
LysoTracker Red labeling
B16F10-Nex2 cells were treated with 0.35 mM AC-1001 H3
or medium (control), simultaneously labeled with 5 lM
LysoTracker Red (Invitrogen) and immediately placed on a
Confocal Leica SP5 microscope, with a 63 9 1.4 oil objec-
tive. Images were taken every 5 min during 22 h, processed
using IMAGEJ and analysis were done using IMARIS (Bitplane
AG, Zurich, Switzerland).
Mass spectrometry
The molecular target of the peptide was identified by mass
spectrometry. B16F10-Nex2 cells (5 9 108) were incubated
with a lysis buffer (1% Triton X-100, 10 mM Tris-HCl,
5 mM EDTA, 50 mM NaCl, 200 lM oxidized glutathione,
pH 7.6) and a mixture of protease inhibitors (Pierce, Rock-
ford, IL, USA) and it was incubated overnight at 4 °C with
biotinylated AC-1001 H3. The lysate was passed through a
column of streptavidin-agarose (Pierce) and eluted with 2%
urea. The eluate was separated in 10% SDS/PAGE, and
the band detected with colloidal Coomassie Blue was sliced
and digested with trypsin (Promega, Fitchburg, WI, USA)
as described elsewhere [18]. An aliquot of the digested
protein (4.5 lL) was injected in the analytic column C18
1.7-lm BEH 130 (100 lm 9 100 mm) RP-UPLC (nanoAc-
quity UPLC; Waters, Milford, MA, USA) coupled to a
Q-TOF Ultima API mass spectrometer (Micro Mass; Waters)
at a flow rate of 600 nLmin1. A trapping column Symme-
try C18 (180 lm 9 20 mm) was used for sample desalting at
a flow rate of 20 lLmin1 over 1 min. The gradient was 0–
50% acetonitrile in 0.1% formic acid over 45 min. The
instrument was operated in MS positive mode, data contin-
uum acquisition from m/z 100–2000 Da at a scan rate of
1 s, and an interscan delay of 0.1 s. Database searches for
peptide identification from LC MS/MS experiments were
done with MASCOT DISTILLER v.2.3.2.0, 2009 (Matrix Science,
Boston, MA, USA) using carbamidomethyl-cys as a fixed
modification (monoisotopic mass 57.0215 Da), methionine
888 FEBS Open Bio 6 (2016) 885–901 ª 2016 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
Apoptotic CDR H3 peptide inhibits melanoma metastasis A. N. Rabaca et al.
oxidation as variable modification (monoisotopic mass
15.9949), and 0.1 Da MS and MS/MS fragment size toler-
ance.
ELISA
The ELISA was performed to determine the binding of
AC-1001 H3 peptide to b-actin. A 96-well opaque plate
(Nunc, Roskilde, Denmark) was coated with AC-1001 H3
or scrambled peptide (500 lgmL1) diluted in carbonate-
bicarbonate buffer, pH 9.2. In the following day, the plate
was washed 59 with 0.1% PBS-Tween (T-PBS) and 5 M
NaCl and blocked at 4 °C with 1% BSA. After 2 h, the
plate was washed again and G-actin or F-actin (Cytoskele-
ton, Denver, CO, USA) was added at 1 : 500 and incu-
bated for 4 h. Anti-actin antibody (Novus Biologicals,
Littleton, CO, USA), at 1 : 1000, was then added for 2 h.
The plate was extensively washed and the secondary anti-
mouse IgG-peroxidase (Sigma-Aldrich) was added
(1 : 1000) for 1 h. After washing with PBS, the reaction
was evaluated by chemoluminescence using ECL (1 : 500;
Millipore) in a luminometer (SpectraMax) at 470 nm.
Synthesis of PLGA nanoparticles
The PLGA Nanoparticles (NPs) containing fluorescent
probe (RhodamineB; Sigma-Aldrich R6626) were synthe-
sized by oil in water emulsification and solvent evaporation
method. Initially, 500 lL of Rhodamine B aqueous solu-
tion (0.5 mM) were added to 20 mL of aqueous solution of
PVA 1% (w/v). Following, 4 mL of PLGA amino termi-
nated solution in dimethylformamide [2.5% (w/v)] was
poured into the PVA/rhodamine solution under stirring.
The emulsion was stirred at room temperature for 17 h.
Then, in order to eliminate microparticles, the suspension
was centrifuged (200 g, 4 °C, 15 min) and the precipitate
was discarded. Finally, NPs were collected by centrifuga-
tion (44 100 g, 15 min, 4 °C). After washing four times
with distilled water, the NPs were suspended in 27 mL of
phosphate buffer saline (PBS). 13.5 mL of NPs suspension
was stored at  4 °C and these NPs were used as blank
control. The other 13.5 mL of NPs suspension were used in
the coupling reaction with AC-1001 H3 peptide
(GQYGNLWFAY).
Coupling AC-1001 H3 to PLGA NPS
Prior to the addition of peptide, PLGA NPs surface
reacted with 1-ethyl-3-[3-dimethylaminopropyl] carbodi-
imide hydrochloride (EDC) (Sigma) and N-hydroxysuccini-
mide (NHS) (Sigma). Firstly, NPs were centrifuged and
resuspended in 13.5 mL of borate buffer solution (pH 7.3),
and then 30 lL of aqueous solution of EDC (1 mM) and
NHS (1 mM) were added to the NPs suspension. After 1 h
under stirring, NPs were centrifuged (44 100 g, 15 min,
4 °C) and resuspended in autoclaved water. Then, 300 lL
of peptide solution (0.75 mM) were added and the mixture
was stirred for 2 h. Finally, NPs-peptide was centrifuged
and resuspended in 13.5 mL of sterilized PBS.
Peptide-NPs-Rhodamine confocal microscopy
B16F10-Nex2 cells (104) were cultivated in round glass cov-
erslips and treated with AC-1001-NPs-Rhodamine solution
for 3 h protected from light at 37 °C. They were then fixed
with 4% formaldehyde for 30 min and permeabilized with
Triton X-100 0.1% for 30 min at room temperature. These
cells were also stained with 1 : 200 Phalloidin-FITC (Molec-
ular Probes) during 1 h at 37 °C in the dark and 1 mgmL1
DAPI (Invitrogen) for 10 min. The coverslips were mounted
on slides with 4 lL of Vectashield (Sigma) and observed in a
Confocal Leica SP5 microscope, with a 63 9 1.4 oil objec-
tive; DAPI was examined at 350 nm excitation and 470 nm
emission, Phalloidin-FITC at 490/520 nm and Peptide-Rho-
damine at 580/604 nm, respectively. The Z series was
obtained according with sampling criteria built in the soft-
ware. Images were processed using IMAGEJ.
Animals and in vivo metastatic model
Six- to eight-week-old male C57BL/6 mice were obtained
from the Center for Development of Experimental Models
(CEDEME, Federal University of S~ao Paulo (UNIFESP),
and kept in isolators, with autoclaved water and food. Ani-
mal experiments were carried out in accordance with the
UNIFESP Ethics Committee for Animal Experimentation
(CEP No. 1807-11). Syngeneic B16F10-Nex2 cells (5 9 105)
cells were injected (in 0.1 mL RPMI without SFB) intra-
venously in the tail veins of mice (n = 5/group) and in the
following day the intraperitoneal treatment (10 consecutive
days) with AC-1001 H3 (300 lgday1 per mouse) started.
The control group received the same volume of the diluting
medium. Five days after the end of treatment, the lungs
were collected and metastatic nodules were counted.
Statistical analysis
The data were expressed as the means  SD. Significant
differences were assessed using Student’s t-test. P-
values < 0.05 were considered significant.
Results
Antimetastatic activity of AC-1001 H3
We demonstrated in the present work that AC-1001
H3 has antimetastatic effects using a syngeneic model
with B16F10-Nex2 cells injected intravenously in male
C57BL/6 mice. The CDR peptide was administered
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intraperitoneally for 10 consecutive days at
300 lgday1 per mouse. After the end of treatment,
the lungs were collected (Fig. 1A) and melanotic meta-
static nodules were counted. There was a significant
difference in the number of nodules between the
untreated (control), and peptide-treated groups
(Fig. 1B). Furthermore, the AC-1001 H3 at a high
dose, 25 mgkg1, was injected for 3 consecutive days
on healthy mice, their organs (liver, heart, kidneys,
spleen, lung and intestine) were collected and examined
for histopathological signs. No alterations were found
(data not shown), suggesting the lack of toxicity of
AC-1001 H3, a promising antitumor drug.
In vitro cytotoxicity
The in vitro cytotoxicity of AC-1001 H3 was tested
on B16F10-Nex2 cells starting with 104 tumor cells
incubated overnight with different concentrations of
the peptide. The cell viability was tested using the
MTT method. The AC-1001 H3 decreased cell via-
bility in a dose-dependent manner and at the highest
concentration allowed by its solubility (0.35 mM), the
peptide killed 50% of the tumor cells. Similarly to
the murine melanoma cells, human A2058 melanoma
cells were equally sensitive to the peptide at IC50
(Fig. 2A). A scrambled peptide did not show any
cytotoxic activity at the same concentration (data
not shown). HUVEC and T75 human endothelial
and fibroblast cell lines, respectively, were
Fig. 1. Antimetastatic effects of peptide AC-1001 H3. Syngeneic
B16F10-Nex2 cells (5 9 105) were injected in C57Bl6 mice (n = 6).
AC-1001 H3 peptide was administered intraperitoneally for 10
consecutive days (300 lgday1 per mouse). Representative
images of lungs (A), and the number of nodules in the lungs of
control and treated animals (B), are shown. A significant reduction
in the number of metastatic nodules was observed (P = 0.0006).
Fig. 2. In vitro cytotoxic activity of AC-1001 H3. (A) B16F10-Nex2
and A2058 cells lines were treated for 18 h with CDR AC-1001 H3,
at concentrations within the solubility limits of the peptide. (B)
AC1001 H3 cytotoxicity in nontumorous cell lines in comparison
with B16F10-Nex2 cell line. Cell viability was determined by MTT
assay. *P < 0.05.
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significantly less affected by the peptide (Fig. 2B).
Cultured cells, however, are a controversial control
of peptide toxicity, which was not observed in vivo
at high concentration of the peptide.
We investigated, therefore, the peptide’s in vitro
mechanism of action using the murine melanoma cell
line. Since 0.35 mM represents the peptide’s solubility
limit and also corresponds to its IC50 in B16F10-Nex2
cells, this concentration was mostly used throughout
this work.
Tumor cell apoptosis
Using Hoechst 33342, a fluorescent dye that interca-
lates within DNA, we observed that ~ 60% of peptide-
treated cells had condensed chromatin (Fig. 3A).
A a a
b
c
d
e
f
b
C D
B
Fig. 3. AC-1001 H3 induces apoptosis. B16F10-Nex2 cells were treated with AC-1001 H3 (0.35 mM) and examined for apoptosis hallmarks.
(A) Untreated (a) and treated (b) cells were stained with Hoechst 33342. Chromatin condensation was observed in treated cells (arrows
indicate cells highlighted in inserts, zoom 700%). Bar, 100 lm. (B) TUNEL assay showing DNA degradation in treated cells (d–f) as
compared to untreated cells (a–c); arrows indicate cells highlighted in inserts, zoom (700%). Bar, 100 lm. (C) Caspase-3, -8 and -9 activation
after peptide treatment, *P < 0.05. (D) Analysis by FACs of peptide-treated cells labeled with annexin V-FITC (AV) and propidium iodide (PI).
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TUNEL assay, used to analyze DNA fragmentation
based on the binding of labeled nucleotides to free
30-OH DNA ends generated during apoptosis,
undoubtedly revealed that AC-1001 H3 treatment
leads to DNA fragmentation, as seen by the green
fluorescence (Fig. 3B).
A colorimetric method was used to measure caspase
activity, which has a critical role in the apoptotic path-
way [19]. Notably, there was a significant increase in
caspases 3, 8, and 9 after AC-1001 H3 treatment, with
levels 3.5-fold, 2-fold, and 3.5-fold higher than the
untreated controls, respectively (Fig. 3C).
Translocation of phosphatidylserine, a well-known
feature of early apoptotic process, and propidium
iodide binding to DNA, a late necrotic event following
disintegration of the plasma membrane, were evaluated
by flow cytometry with Annexin V and propidium
iodide labeling. An increase in annexin V positive cells
after AC-1001 H3 treatment (11.7%) as compared to
the untreated control (2.25%) or the scrambled peptide
(4.48%), was observed. Double labeled, annexin V,
and PI positive cells, however, increased up to 38.9%
in treated cells as compared to 11.6% (control) and
13% (scrambled peptide) (Fig. 3D).
AC-1001 H3 also induced apoptosis in A2058 cells.
Cells treated with AC-1001 H3 (0.35 mM) showed
chromatin condensation and positive TUNEL assay
reactivity (Fig. 4).
Superoxide anions formation and mitochondria
interference
Reactive oxygen species production was detected by
DHE (dihydroethidium), which is oxidized to ethidium
by superoxide anions, emitting red fluorescence.
Increased superoxide anions formed after AC-1001 H3
treatment (Fig. 5A).
Dissipation of the mitochondrial membrane poten-
tial was estimated by TMRE (tetramethylrhodamine
ethyl ester) staining. The dye accumulates in active
mitochondria but not in depolarized mitochondria.
Flow cytometry analysis showed fluorescence reduction
in AC-1001 H3 treated cells as compared to control
and scrambled peptide-treated cells (Fig. 5B) thus indi-
cating lower TMRE accumulation and mitochondrial
membrane depolarization induced by AC-1001 H3.
Ultrastructural effects of AC-1001 H3
Control and peptide-treated cells were also analyzed
through transmission electron microscopy (TEM;
Fig. 6). Chromatin condensation (CC), nuclear frag-
mentation (NF), nuclear membrane disintegration
(MD), formation of cytoplasmic vacuoles (V), and
blebs (B) are typical apoptotic morphological alter-
ations that were found and they corroborate biochemi-
cal determinations. Further observation, however,
A
a
b
a
b
c
d
B
Fig. 4. AC-1001 H3 also induces apoptosis in A2058 cells. Cells were treated with AC-1001 H3 (0.35 mM) and examined for apoptosis
hallmarks. (A) Untreated (a) and treated (b) cells were stained with Hoechst 33342. Chromatin condensation was observed in treated cells
(white arrows) Bar, 20 lm. (B) TUNEL assay showing DNA degradation in treated cells (c, d) as compared to untreated cells (a, b). Bar,
20 lm.
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showed that in addition to the cytoplasmic vacuola-
tion, structures similar to autophagic vacuoles were
also seen.
Peptide-induced signs of autophagy
Cells were incubated with antibodies against LC3 and
Beclin 1 proteins, which are essential for autophago-
some formation. Using confocal microscopy, we
demonstrated an enhanced expression of LC3 and
Beclin 1 proteins on peptide-treated cells (Fig. 7A,B).
Since LC3-II, formed by conjugation with phos-
phatidylethanolamine, is a marker of the elongation
phase of the isolation membrane to capture damaged
organelles or cytosolic materials, it indicates an
increase in the rate of autophagosome formation [20].
Western blotting analysis of LC3 expression (Fig. 7C)
showed an increase in the expression of LC3-II
(16 kDa) in AC-1001 H3 treated cells. Quantification
showed a value 1.8-fold higher than in untreated cells.
We also used Lysotracker Red for labeling acidic
organelles in live cells. Using IMARIS software to quan-
tify the number of acidic organelles based on the cell
volume, we did not find a significant difference in con-
trol or treated cells, which could indicate poor
transition into autolysosomes for degradation of cap-
tured materials or a blockade of autophagosome matu-
ration. When the fluorescence intensity was measured
as indicated in Fig. 7D, a few peptide-treated cells
showed higher acidity as compared to control cells.
Further studies are needed, however, to confirm the
autophagy flux in peptide-treated tumor cells.
Time-dependent expression of Beclin 1 and
caspase 3
The expression of Beclin 1 and caspase 3 was followed
at 0, 4, 8, and 16 h in both B16F10-Nex2 and A2058
cell lines incubated with Ac-1001 H3 (Fig. 8A,B). The
endogenous expression of Beclin 1 was high in
B16F10-Nex2 and low in A2058 lysates. In the absence
of autophagy Beclin 1 could be bound to Bcl-2 or Bcl-
XL [21], which are also highly expressed in B16F10
cells [22] (V.S.C. Maia, unpublished result). In A2058
human melanoma cells, the expression of Beclin 1
increased at 4 h incubation with the peptide. In both
cases, after 8 h, there was a progressive degradation of
Beclin 1 simultaneously with the increasing expression
procaspase 3, which cleaves Beclin 1, clearly indicating
that the apoptosis process develops after the observed
signs of autophagy described above.
AC-1001 H3 cell ligand
In order to better understand the peptide’s mechanism
of action, we investigated possible ligands in tumor
cells. Lysed B16F10-Nex2 cells were incubated with
biotinylated AC-1001 H3, passed through a strepta-
vidin-Agarose column and eluted with 2% urea. The
eluate was separated in 10% SDS/PAGE. The only
detected band was digested with trypsin and analyzed
by Q-TOF mass spectrometry. We found three pep-
tides that matched with b-actin, suggesting it to be the
main target of AC-1001 H3 (Fig. 9A). It was con-
firmed by the strong binding of AC-1001 H3 peptide
to both G- and F-actin in an ELISA assay (Fig. 9B)
and by confocal microscopy, using peptide-NPs-rhoda-
mine labeling (Fig. 9C). Cells were treated with
AC-1001-NPs-Rhodamine (Fig. 9C-a) solution for 3 h,
fixed, permeabilized, and stained with phalloidin-
FITC, used to identify filamentous actin (Fig. 9C-b).
Merged images (Fig. 9C-c) showed colocalization of
AC-1001 H3 peptide and F-actin in white.
Inhibition of tumor cell migration
Using the images obtained with lysotracker a video
was prepared with control and peptide-treated
A
a b c
B
Fig. 5. Anion superoxide production and mitochondrial effects
induced by AC-1001 H3. B16F10-Nex2 cells were treated with AC-
1001 H3 (0.35 mM) for 12–18 h. (A) Anion superoxide production
induced by peptide treatment; (a), untreated cells; (b) positive
control with 5 mM H2O2; (c) AC-1001 H3. Bar, 50 lm. (B)
Mitochondrial transmembrane-potential (Dwm) dissipation.
Untreated cells (blue), AC-1001 H3 (green) and scramble peptide
(red).
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melanoma cells (Video S1). It was evident that AC-
1001 H3 treatment, by interacting with key compo-
nents of the cell skeleton, caused cell shrinkage and
promptly inhibited cell migration. White asterisks indi-
cate migration and duplication of control cells
(Fig. 10), whereas no alterations were seen in peptide-
treated cells.
Discussion
Peptides have attracted attention as anticancer drugs
due to their versatility in terms of synthesis and
derivatization. Janin [23] reviewed a range of
characterized peptides that have established or poten-
tial anticancer use. Mechanisms of action allowed their
classification as receptor-interacting compounds,
inhibitors of protein-protein interaction, enzyme inhi-
bitors, nucleic acid-interacting compounds. Bhutia and
Maiti emphasized the potential of novel peptides,
derived from natural sources [9]. As reviewed by these
authors, anticancer cytotoxicity includes tumor cell
necrosis, apoptosis, function blocking, and the inhibi-
tion of angiogenesis, besides immune stimulation.
The potential of immunoglobulins as a source of
bioactive peptides is based on the pivotal work by
Polonelli et al. [24] on fragments of an antiidiotypic
A B
C D
E F
Fig. 6. Cell structure effects induced by
AC-1001 H3. B16F10-Nex2 cells were
treated with AC-1001 H3 (0.35 mM) and
observed by transmission electron
microscopy. (A, B) untreated cells; (C)
nuclear membrane disruption (NMD) and
chromatin condensation (CC) in treated
cells; (D) mitochondria disintegration (MD)
and blebs (B); (E) autophagic vacuoles
(AV); (F) nuclear fragmentation (NF),
chromatin condensation (CC) and vacuoles
(V). Bar, 0.5 lm.
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antibody, in particular an engineered killer peptide
that displayed a broad antimicrobial activity [24]. This
was extended to CDRs from unrelated murine and
human monoclonal Abs, which, irrespective of the
native Ab specificity, displayed in vitro, in vivo, and/or
ex vivo antifungal (Candida albicans), antiviral (HIV-
1), and antitumor (melanoma) activities [10,11]. Recep-
tors on target cells for the Ig-derived peptides and
their effects on cell function are slowly being recog-
nized [12,15,25,26]. In melanoma cells, CDRs from dif-
ferent monoclonal antibodies bound to protocadherin
beta-13, histone-1, beta-actin, tubulin, HSP90, and
GPR124 [12,25] (N. Girola and L.R. Travassos,
unpublished results). Arruda et al. [25] demonstrated
that the peptide based on CDR H2 from mAb C7,
against C. albicans, induced apoptosis in tumor cell
lines by b-actin binding and disturbing actin dynamics.
It also displayed an important antimetastatic activity
[25].
The potential of the synthetic peptide AC-1001-H3
(based on mouse mAb AC-1001 CDR H3) as an anti-
tumor drug, was explored in this article. Initially we
evaluated its activity in vitro on tumor and nontumor
cell lines, treated overnight at different peptide concen-
trations. We observed that AC-1001 H3 was cytotoxic
in tumor cells and significantly less effective in nontu-
mor cell lineages.
Using the murine B16F10-Nex2 melanoma cell line,
we focused on the apoptotic death pathway as a possi-
ble mechanism for action of the peptide. Apoptosis is
a highly coordinated type of cell death triggered by
various stimuli, activating either the extrinsic death
receptor pathway or the intrinsic mitochondrial path-
way. It involves the activation of caspases and a cas-
cade of events that culminate in cell demise [27,28].
Chromatin condensation, DNA fragmentation, activa-
tion of caspases-3, -8, and -9, external translocation of
phosphatidylserine, increased ROS production and dis-
sipation of the mitochondrial transmembrane potential
were effects induced by the peptide strongly suggesting
A
B
C
a b
D
a
b
a
b
Fig. 7. AC-1001 H3 induces autophagy. B16F10-Nex2 cells were
treated with AC-1001 H3 (0.35 mM) overnight. Beclin 1 (A) and LC3
(B) proteins were analyzed by confocal microscopy using specific
antibodies. (a) untreated and (b) treated cells. Bar, 20 lm. (C)
Immunoblotting analysis of LC3-I (18 kDa) and LC3-II (16 kDa)
expression, using anti-GAPDH as protein loading control (a).
Quantification of band area intensity (b). (D) Cells were incubated
with AC-1001 H3 peptide or untreated control (C) cells and
simultaneously labeled with 5 lM LysoTracker Red. Images were
taken every 5 min in a confocal microscopy and the fluorescence
was measured using IMARIS software. C (black) – untreated cells;
T1–T5 (color) – individually represented cells.
895FEBS Open Bio 6 (2016) 885–901 ª 2016 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
A. N. Rabaca et al. Apoptotic CDR H3 peptide inhibits melanoma metastasis
the intrinsic apoptosis pathway. TEM, considered as
the ‘gold standard’ assay to confirm the cell death
mechanism [29], was also performed. Alterations in the
cell ultrastructure were observed including condensed
chromatin, nuclear membrane disintegration, nuclear
fragmentation, and plasma membrane blebbing, some
well-known features of apoptosis [28,30,31]. The
human melanoma cell line A2058 was equally affected
by AC 1001 H3 at the same cytotoxic concentration
showing condensed chromatin and a positive TUNEL
assay for DNA degradation.
Features of different types of cell death can overlap in
certain cases, so that different assays are important to
allow an accurate interpretation [27]. Our results showed
both AV+/PI and AV+/PI+ cells upon AC-1001 H3
treatment, suggesting necrosis, with plasmatic membrane
disintegration. In fact, cultured cells undergoing apopto-
sis in vitro will eventually undergo secondary time-
dependent necrosis [27]. The AV+/PI+ cells, as observed,
may represent a late apoptosis, with alterations in the
membrane’s integrity [32] or an aponecrosis, combining
apoptosis, and necrosis [33]. Since membrane alterations
are relatively common in adherent cells cultured in vitro,
annexin-V and PI positive cells in a flow cytometry anal-
ysis are usually regarded as apoptotic [34,35].
As to caspase activation, the peptide induced the
upstream initiators caspase-8 and -9 and the down-
stream execution caspase-3, with a more emphatic
increase in caspase-9 and -3. Caspase-8 is associated
with the extrinsic pathway of apoptosis, while caspase-
9 is related to the intrinsic pathway [19]. As previously
described, there may be a crosstalk between both
apoptotic pathways mediated by Bid [36,37]. Alterna-
tively, caspase-8 could be triggered by ROS, mediating
the mitochondrial pathway and bypassing CD95/Fas
engagement [25,38,39]. It has also been reported the
possibility of an interdependence of caspase-2, -8, -9,
and -3 in an apoptotic process mediated by ROS
[17,40]. Once we also had mitochondrial transmem-
brane-potential dissipation and increased ROS produc-
tion, the apoptosis induced by AC-1001 H3 likely
occurred via the intrinsic pathway and caspase-8 acti-
vation was induced by ROS.
Transmission electron microscopy analysis addition-
ally revealed a massive cell vacuolization and orga-
nelles within some vesicles, seemingly autophagy
suggesting images [41–43]. Through autophagy, pro-
teins and organelles are sequestered into double mem-
brane vesicles (autophagosomes) and are subsequently
delivered to the lysosomes for degradation [44]. It is
an evolutionary conserved process that occurs in all
eukaryotic cells and is characterized by the accumula-
tion of autophagic vesicles [45]. Studies in yeast
allowed the identification of evolutionary conserved
autophagy-related (Atg) genes that control major steps
in the process [46]. Beclin 1 is a mammalian ortholog
of yeast Atg6 and is required for autophagosome for-
mation. Microtubule-associated protein 1 light chain 3
(LC3) is the ortholog of yeast Atg8 [45].
We have shown by fluorescence microscopy the
increased expression of Beclin 1 and LC3 expression
after peptide treatment. Interestingly, some anticancer
drugs that induce autophagy may act through the up-
regulation of Beclin 1, as exemplified for the ceramide-
mediated process induced by tamoxifen [47]. Kabeya
et al. described that LC3-I and LC3-II are generated
by post-translational modifications and that LC3-I (cy-
tosolic) is converted to LC3-II (membrane bound),
localized in autophagosome membranes. There is a
correlation between LC3-II and elongation of the iso-
lation membrane, hence of autophagosome formation,
which makes LC3-II a good marker for autophago-
somes [20]. To support the previous result, we also
showed by western blotting, two bands at 18 kDa
(LC3-I) and 16 kDa (LC3-II). Their quantification
showed a substantial increase in LC3-II expression,
Fig. 8. Kinetics of Beclin 1 and caspase 3 expression in melanoma cell lines. B16F10-Nex2 (A), and A2058 (B) tumor cells (5 9 104) were
treated with 0.35 mM of AC1001 peptide for 4, 8 and 16 h. After treatment, proteins in cell lysates were analyzed by western blotting.
a-tubulin was used as loading control. Secondary antibodies were conjugated with IgG horseradish peroxidase.
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which may indicate enhanced autophagosome assem-
bly. Since the autophagic flux was not further explored
it is unclear whether, in this experiment, increased
levels of LC3-II might otherwise reflect accumulation
of autophagosomes due to downstream blockade of
autolysosome formation [48]. Such interference in the
A
B a
b
C
a
c
b
Fig. 9. AC-1001 H3 binding to b-actin. B16F10-Nex2 cell lysate was incubated with biotinylated AC-1001 H3. Proteins were separated in
streptavidin-Agarose and eluted with urea. The eluate was separated in SDS/PAGE, and the single band detected was analyzed by mass
spectrometry. (A) Peptides from LC MS/MS leading to b-actin identification are shown, over the entire sequence, in red. (B) AC-1001 H3
and b-actin binding was confirmed by ELISA using G-actin (a) or F-actin (b). *P < 0.05. (C) Confocal microscopy showing F-actin and AC-
1001 H3 co-localization. B16F10-Nex2 cells were incubated with peptide-NPs-rhodamine (a) according to experimental procedures and also
stained with Phalloidin-FITC. (b) Merge (c) Showing co-localization points in white and highlighted below (1 and 2). Bar 20 lm (a–c), and
60 lm (1 and 2).
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maturation step could well occur by the mechanism of
action of AC 1001 H3, primarily based on b-actin
binding. In fact, both G- and F-actin are ligands to
the peptide. By targeting actin, apart from the effects
on microtubule distribution [49], the peptide might
also target actin-related proteins of the dynactin com-
plex [50] which, with dynein, drive autophagosomes on
microtubules to the cell center where most lysosomes
are [51]. Such hypotheses require further experiments
for validation. Peptide-treated cells stained with lyso-
tracker red, a lysosomotropic agent, did not show an
increase in the number of acidic organelles, but some
individual cells had a more intense fluorescence mea-
surement. These results describe autophagy induction
signs but are insufficient to confirm a complete autop-
hagy flux in response to the CDR peptide that acts on
the actin framework, inhibits cell migration (Video S1)
and elicits tumor cell apoptosis. The signs of autop-
hagy clearly precede the apoptosis process as shown
by Beclin 1 expression in both B1F10-Nex2 and A2058
cell lines as well as its degradation simultaneously with
caspase 3 expression. Caspase-mediated cleavage of
beclin 1 promotes the crosstalk between apoptosis and
autophagy [21].
Fig. 10. AC-1001 H3 inhibits cell migration. B16F10-Nex2 cells treated with 0.35 mM AC-1001 H3 were labeled with 5 lM lysotracker.
Images were taken every 5 min in a confocal microscope in real time. White asterisks indicate untreated cells migrating and duplicating in
contrast with treated cells. Bar, 100 lm. The time of incubation in each image is indicated.
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One of the major functions of autophagy is to keep
cells alive under stressful ‘life-threatening conditions’
as stated by Kroemer and Levine [52]. A significant
decrease in tumor growth in mice treated with the
autophagy inhibitor hydroxychloroquine (HCQ) was
reported [53]. These observations agree with other
reports showing that HCQ inhibits in vitro cell growth
and in vivo tumor growth via induction of apoptosis.
Inhibition of autophagy promotes cancer cell death
[54] and potentiates anticancer treatments. Several arti-
cles have addressed the combination of apoptosis and
autophagy [30,42,43,55–57]. Finally and most impor-
tantly, we studied the peptide effect in vivo in a syn-
geneic model. AC-1001 H3 was able to inhibit
metastasis, leading to a significant decrease in the
number of lung nodules in mice treated with the pep-
tide in comparison to the untreated control. No toxic
effects were observed during the treatment protocol,
even by histopathological inspection of mice organs.
Moreover, injection of a high dose of the peptide into
healthy animals also did not show histological alter-
ations.
In conclusion, we suggest that AC-1001 H3 targets
b-actin in melanoma cells, induces apoptosis after
signs of autophagy in tumor cells while exerting little
cytotoxicity in non-tumorigenic cells in vitro and no
observed toxicity in vivo in healthy animals. It exhibits
a potent antimetastatic effect in vivo and can be con-
sidered a promising candidate for drug development in
cancer therapy.
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Supporting information
Additional Supporting Information may be found
online in the supporting information tab for this arti-
cle:
Video S1. AC-1001 H3 causes cell shrinkage and inhi-
bits cell migration. B16F10-Nex2 cells were treated
with 0.35 mM AC-1001 H3, simultaneously labeled
with 5 lM lysotracker and examined in a confocal
microscopy. Images were taken during 22 h every
5 min and a video setting was prepared using IMARIS
software.
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